Bovine Lactoferrin Induces Cell Cycle Arrest and Inhibits Mtor Signaling in Breast Cancer Cells

REFERENCES

• Milner JA: Molecular targets for bioactive food components. J Nutr 134, 2492S–2498S, 2004.
   PubMed Web of Science ®Google Scholar
• Patel B, Das S, and Prakash R: Natural bioactive compound with anticancer potential. Int J Adv Pharm Sci 1, 32–41, 2010.
   Google Scholar
• Young SK and Milner JA: Bioactive food components and cancer-specific metabonomic profiles. J Biomed Biotechnol. Advanced online publication. doi: http://dx.doi.org/10.1155%2F2011%2F721213. 2011.
   Google Scholar
• Dennis T, Fanous M, and Mousa S: Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutr Cancer 61, 587–597, 2009.
   PubMed Web of Science ®Google Scholar
• Pan MH, Lai CS, Tsai ML, Wu JC, and Ho CT: Molecular mechanisms for anti-aging by natural dietary compounds. Mol Nutr Food Res 56, 88–115, 2012.
   PubMed Web of Science ®Google Scholar
• Adlerova L, Bartoskova A, and Faldyna M: Lactoferrin: a review. Veterinarni Medicina 53, 457–468, 2008.
   Web of Science ®Google Scholar
• Ushida Y, Sekine K, Kuhara T, Takasuka N, Iigo M, et al.: Possible Chemopreventive Effects of Bovine Lactoferrin on Esophagus and Lung Carcinogenesis in the Rat. Jpn J Cancer Res 90, 262–267, 1999.
   PubMedGoogle Scholar
• Kuhara T, Iigo M, Itoh T, Ushida Y, Sekine K, et al.: Orally administered Lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the Intestinal epithelium. Nutr Cancer 38, 192–199, 2000.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Monitto CL, Minhas KM, and Sidransky D: Lactoferrin down-regulates G1 cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin Cancer Res 10, 8683–8686, 2004.
   PubMed Web of Science ®Google Scholar
• Chandra Mohan KV, Kumaraguruparan R, Prathiba D, and Nagini S: Modulation of xenobiotic-metabolizing enzymes and redox status during chemoprevention of hamster buccal carcinogenesis by bovine lactoferrin. Nutrition 22, 940–946, 2006.
   PubMed Web of Science ®Google Scholar
• Tomita M, Wakabayashi H, Yamauchi K, Teraguchi S, and Hayasawa H: Bovine lactoferrin and lactoferricin derived from milk: production and applications. Biochem Cell Biol 80, 109–112, 2002.
   PubMed Web of Science ®Google Scholar
• Rodrigues L, Teixeira J, Schmitt F, Paulsson M, and Månsson HL: Lactoferrin and cancer disease prevention. Crit Rev Food Sci Nutr 49, 203–217, 2009.
   PubMed Web of Science ®Google Scholar
• Tsuda H, Kozu T, Iinuma G, Ohashi Y, Saito Y, et al.: Cancer prevention by bovine lactoferrin: from animal studies to human trial. Biometals 23, 399–409, 2010.
   PubMed Web of Science ®Google Scholar
• Roy MK, Kuwabara Y, Hara K, Watanabe Y, and Tamai Y: Peptides from the N-terminal end of bovine lactoferrin induce apoptosis in human leukemic (HL-60) cells. J Dairy Sci 85, 2065–2074, 2002.
   PubMed Web of Science ®Google Scholar
• Onishi J, Roy MK, Juneja LR, Watanabe Y, and Tamai Y: A lactoferrin-derived peptide with cationic residues concentrated in a region of its helical structure induces necrotic cell death in a leukemic cell line (HL-60). J Pept Sci 14, 1032–1038, 2008.
   PubMed Web of Science ®Google Scholar
• Fillebeen C, Descamps L, Dehouck MP, Fenart L, Benaïssa M, et al.: Receptor-mediated transcytosis of lactoferrin through the blood–brain barrier. J Biol Chem 274, 7011–7017, 1999.
   PubMed Web of Science ®Google Scholar
• Jiang R, Lopez V, Kelleher SL, and Lönnerdal B: Apo- and holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERK-signaling and cell proliferation in Caco-2 cells. J Cell Physiol 226, 3022–3031, 2011.
   PubMed Web of Science ®Google Scholar
• Rochard E, Legrand D, Lecocq M, Hamelin R, Crepin M, et al.: Characterization of lactotransferrin receptor in epithelial cell lines from non-malignant human breast, benign mastopathies and breast carcinomas. Anticancer Res 12, 2047–2051, 1992.
   PubMed Web of Science ®Google Scholar
• Bi BY, Liu JL, Legrand D, Roche AC, Capron M, et al.: Internalization of human lactoferrin by the Jurkat human lymphoblastic T-cell line. Eur J Cell Biol 69, 288–296, 1996.
   PubMed Web of Science ®Google Scholar
• Damiens E, Mazurier J, el Yazidi I, Masson M, Duthille I, et al.: Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumour cells. Biochim Biophys Acta 1402, 277–287, 1998.
   PubMed Web of Science ®Google Scholar
• Lin TY, Chiou SH, Chen M, and Kuo CD: Human lactoferrin exerts bi-directional actions on PC12 cell survival via ERK1/2 pathway. Biochem Biophys Res Commun 337, 330–336, 2005.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zeng Z, Zhang W, Xiong W, Wu M, et al.: Lactotransferrin: a candidate tumor suppressor-deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer 123, 2065–2072, 2008.
   PubMed Web of Science ®Google Scholar
• Xu XX, Jiang HR, Li HB, Zhang TN, Zhou Q, et al.: Apoptosis of stomach cancer cell SGC-7901 and regulation of Akt signaling way induced by bovine lactoferrin. J Dairy Sci 93, 2344–2350, 2010.
   PubMed Web of Science ®Google Scholar
• Damiens E, El Yazidi I, Mazurier J, Duthille I, Spik G, et al.: Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. J Cell Biochem 74, 486–498, 1999.
   PubMed Web of Science ®Google Scholar
• Sakai T, Banno Y, Kato Y, Nozawa Y, and Kawaguchi M: Pepsin-digested bovine lactoferrin induces apoptotic cell death with JNK/SAPK activation in oral cancer cells. J Pharmacol Sci 98, 41–48, 2005.
   PubMed Web of Science ®Google Scholar
• Furlong SJ, Mader JS, and Hoskin DW: Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen. Oncol Rep 15, 1385–1390, 2006.
   PubMed Web of Science ®Google Scholar
• Lee SH, Park SW, Pyo CW, Yoo NK, Kim J, et al.: Requirement of the JNK-associated Bcl-2 pathway for human lactoferrin-induced apoptosis in the Jurkat leukemia T cell line. Biochimie 91, 102–108, 2009.
   PubMed Web of Science ®Google Scholar
• Duarte DC, Nicolau A, Teixeira JA, and Rodrigues LR: The effect of bovine milk lactoferrin on human breast cancer cell lines. J Dairy Sci 94, 66–76, 2011.
   PubMed Web of Science ®Google Scholar
• Furmanski P, Li ZP, Fortuna MB, Swamy CV, and Das MR: Multiple molecular forms of human lactoferrin. Identification of a class of lactoferrins that possess ribonuclease activity and lack iron-binding capacity. J Exp Med 170, 415–429, 1989.
   PubMed Web of Science ®Google Scholar
• Siebert PD and Huang BC: Identification of an alternative form of human lactoferrin mRNA that is expressed differentially in normal tissues and tumor-derived cell lines. Proc Natl Acad Sci U S A 94, 2198–2203, 1997.
   PubMed Web of Science ®Google Scholar
• Hoedt E, Hardivillé S, Mariller C, Elass E, Perraudin JP, et al.: Discrimination and evaluation of lactoferrin and delta-lactoferrin gene expression levels in cancer cells and under inflammatory stimuli using TaqMan real-time PCR. Biometals 23, 441–452, 2010.
   PubMed Web of Science ®Google Scholar
• Breton M, Mariller C, Benaïssa M, Caillaux K, Browaeys E, et al.: Expression of delta-lactoferrin induces cell cycle arrest. Biometals 17, 325–329, 2004.
   PubMed Web of Science ®Google Scholar
• O’Connor PM, Jackman J, Bae I, Myers TG, Fan S, et al.: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57, 4285–4300, 1997.
   PubMed Web of Science ®Google Scholar
• Weigel RJ and deConinck EC: Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer Res 53, 3472–3474, 1993.
   PubMed Web of Science ®Google Scholar
• Ford CH, Al-Bader M, Al-Ayadhi B, and Francis I: Reassessment of estrogen receptor expression in human breast cancer cell lines. Anticancer Res 31, 521–527, 2011.
   PubMed Web of Science ®Google Scholar
• Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, et al.: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF10. Cancer Res 50, 6075–6086, 1990.
   PubMed Web of Science ®Google Scholar
• Hackett AJ, Smith HS, Springer EL, Owens RB, Nelson-Rees WA, et al.: Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines. J Natl Cancer Inst, 58, 1795–1806, 1977.
   PubMed Web of Science ®Google Scholar
• Schägger H: Tricine-SDS-PAGE. Nat Protoc 1, 16–22, 2006.
   PubMed Web of Science ®Google Scholar
• Xavier CP, Lima CF, Fernandes-Ferreira M, and Pereira-Wilson C: Salvia fruticosa, Salvia officinalis, and rosmarinic acid induce apoptosis and inhibit proliferation of human colorectal cell lines: the role in MAPK/ERK pathway. Nutr Cancer 61, 564–571, 2009.
   PubMed Web of Science ®Google Scholar
• Kanwar JR, Palmano KP, Sun X, Kanwar RK, Gupta R, et al.: ‘Iron-saturated’ lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunol Cell Biol 86, 277–288, 2008.
   PubMed Web of Science ®Google Scholar
• Li S, Zhou H, Huang G, and Liu N: Inhibition of HBV infection by bovine lactoferrin and iron-, zinc-saturated lactoferrin. Med Microbiol Immunol 198, 19–25, 2009.
   PubMed Web of Science ®Google Scholar
• Foley AA, Bates GW: The purification of lactoferrin from human whey by batch extraction. Anal Biochem 162, 296–300, 1987.
   PubMed Web of Science ®Google Scholar
• Yang N, Lejon T, and Rekdal O: Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. J Pept Sci 9, 300–311, 2003.
   PubMed Web of Science ®Google Scholar
• Duchardt F, Ruttekolk IR, Verdurmen WP, Lortat-Jacob H, Bürck J, et al.: A cell-penetrating peptide derived from human lactoferrin with conformation-dependent uptake efficiency. J Biol Chem 284, 36099–36108, 2009.
   PubMed Web of Science ®Google Scholar
• Freiburghaus C, Janicke B, Lindmark-Månsson H, Oredsson S, and Paulsson MA: Lactoferricin treatment decreases the rate of cell proliferation of a human colon cancer cell line. J Dairy Sci 92, 2477–2484, 2009.
   PubMed Web of Science ®Google Scholar
• Yang N, Stensen W, Svendsen JS, and Rekdal Ø: Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. J Pept Res 60, 187–197, 2002.
   PubMedGoogle Scholar
• Zhang TN, Yang W, and Liu N: Effect of loop structure of bovine lactoferricin on apoptosis in Jurkat cells. Biometals 23, 555–561, 2010.
   PubMed Web of Science ®Google Scholar
• Cai B, Chang SH, Becker EB, Bonni A, and Xia Z: p38 MAP kinase mediates apoptosis through phosphorylation of BimEL at Ser-65. J Biol Chem 281, 25215–25222, 2006.
   PubMed Web of Science ®Google Scholar
• Worster DT, Schmelzle T, Solimini NL, Lightcap ES, Millard B, et al.: Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2. Sci Signal 5, ra19, 2012.
   PubMed Web of Science ®Google Scholar
• Tokunaga C, Yoshino K, and Yonezawa K: mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun 313,443–446, 2004.
   PubMed Web of Science ®Google Scholar
• Morgensztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16, 797–803, 2005.
   PubMed Web of Science ®Google Scholar
• Vollenbröker B, George B, Wolfgart M, Saleem MA, Pavenstädt H, et al.: mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 296, F418–F426, 2009.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Gulhati P, Arrieta I, Wang X, Uchida T, et al.: Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res 29, 3185–3190, 2009.
   PubMed Web of Science ®Google Scholar
• Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, et al.: Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10, 1013–1023, 2004.
   PubMed Web of Science ®Google Scholar
• Shackelford DB and Shaw RJ: The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9, 563–575, 2009.
   PubMed Web of Science ®Google Scholar
• Tamura K, Southwick EC, Kerns J, Rosi K, Carr BI, et al.: Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res 60, 1317–1325, 2000.
   PubMed Web of Science ®Google Scholar
• Sun X, Jiang R, Przepiorski A, Reddy S, Palmano KP, et al.: “Iron-saturated” bovine lactoferrin improves the chemotherapeutic effects of tamoxifen in the treatment of basal-like breast cancer in mice. BMC Cancer 12, 591, 2012.
   PubMed Web of Science ®Google Scholar
• Baker EN and Baker HM: A structural framework for understanding the multifunctional character of lactoferrin. Biochimie 91, 3–10, 2009.
   PubMed Web of Science ®Google Scholar
• Link G, Saada A, Pinson A, Konijn AM, and Hershko C: Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J Lab Clin Med 131, 466–474. 1998.
   PubMed Web of Science ®Google Scholar
• He WL, Feng Y, Li XL, Wei YY, and Yang XE: Availability and toxicity of Fe(II) and Fe(III) in Caco-2 cells. J Zhejiang Univ Sci B 9, 707–712, 2008.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Sato R, Kobayashi S, Hankanga C, Inanami O, et al.: The antiproliferative effect of bovine lactoferrin on canine mammary gland tumor cells. J Vet Med Sci 70, 443–448, 2008.
   PubMed Web of Science ®Google Scholar
• Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, et al.: DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18, 7883–7899, 1999.
   PubMed Web of Science ®Google Scholar
• Igney FH and Krammer PH: Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 71, 907–920, 2002.
   PubMed Web of Science ®Google Scholar
• Gasco M, Shami S, and Crook T: The p53 pathway in breast cancer. Breast Cancer Res 4, 70–76, 2002.
   PubMed Web of Science ®Google Scholar
• Meulmeester E, Jochemsen AG: p53: a guide to apoptosis. Curr. Cancer Drug Tar 8, 87–97, 2008.
   PubMed Web of Science ®Google Scholar
• Jänicke RU: MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat 117, 219–221, 2009.
   PubMed Web of Science ®Google Scholar
• Roy SK, Srivastava RK, and Shankar S: Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 5, 10, 2010.
   PubMedGoogle Scholar
• Kim J, Kundu M, Viollet B, and Guan KL: AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13, 132–141, 2011.
   PubMed Web of Science ®Google Scholar
• Mulder AM, Connellan PA, Oliver CJ, Morris CA, and Stevenson LM: Bovine lactoferrin supplementation supports immune and antioxidant status in healthy human males. Nutr Res 28, 583–589, 2008.
   PubMed Web of Science ®Google Scholar
• Wang YY and Malik R: Safety and Efficacy of Talactoferrin in Previously Treated Patients with Non-Small Cell Lung Cancer (FORTIS-M). Clinical trials, Gov. registration number: NCT00707304.
   Google Scholar
• Wang YY and Malik R. Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients with Non-Small Cell Lung Cancer (FORTIS-C). Clinical trials, Gov. registration number: NCT00706862.
   Google Scholar
• Nozaki A, Ikeda M, Naganuma A, Nakamura T, and Inudoh M: Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. J Biol Chem 278, 10162–10173, 2003.
   PubMed Web of Science ®Google Scholar